Ranjith Shetty, MD
Interventional Cardiology · Tucson, AZNPI 1316041270
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Edwards Lifesciences at 46.6% of the total. Reporting peaked in 2019 at $31,800 and has fallen 96.2% since, to $1,214 in 2025.
Across 256 payments — averaging $193.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$23K
- Medtronic$20K
- Abiomed$2K
- Boston Scientific$1K
- Abbott$1K
- Heartflow, Inc.$461
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$21,47543%
- Travel & lodging$15,70832%
- Food & beverage$12,43425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 67 | $23,126 |
| Medtronic(2 entities) | 89 | $20,248 |
| Abiomed | 16 | $1,548 |
| Boston Scientific | 22 | $1,459 |
| Abbott | 23 | $1,065 |
| Heartflow, Inc. | 5 | $461 |
| Philips North America LLC | 7 | $445 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $242 |
| Novartis | 5 | $195 |
| Atricure, Inc. | 1 | $136 |
| W. L. Gore & Associates, Inc. | 1 | $118 |
| Chiesi USA, Inc. | 1 | $116 |
| Inari Medical, Inc. | 1 | $113 |
| Kestra Medical Technology Services, Inc. | 3 | $103 |
| Asahi Intecc USA, Inc. | 1 | $74 |
| Cardiva Medical, Inc. | 1 | $28 |
| Cvrx, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $25 |
| Biosense Webster, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Amgen | 1 | $16 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$21,104
- CoreValve Evolut$13,577
- COREVALVE EVOLUT R$4,393
- Impella$984
- Watchman$735
- Mitra Clip system$288
- FFRct$247
- SYMPLICITY G3$192
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$136
- WATCHMAN Access System$133
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$132
- MitraClip System$126
- ENTRESTO$125
- AVEIR$125
- CARDIOFORM Septal Occluder$118
- KENGREAL$116
- FlowTriever$113
- ClotTriever$113
- IGT D Coronary$110
- Resolute$110
How this compares
$49,618 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $31,319 |
| BrilintaTicagrelor | 24 | $23,489 |
| Metoprolol Succinate | 38 | $480 |
| ClopidogrelClopidogrel Bisulfate | 32 | $288 |
| Amlodipine Besylate | 11 | $37 |
| Furosemide | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $16 | $23,48924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- Dexter de LeonTucson$74K
- William ThomasTucson$56K
- Santiago RamirezTucson$45K
- Sulaiman RathoreTucson$32K
- Michel CorbanTucson$27K
- Sundeep ShenoyTucson$24K
- Paul SorajjaPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.